- Hepion Pharmaceuticals Inc HEPA stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial.
- Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of cyclophilins involved in many disease processes.
- As previously disclosed, the trial achieved all primary endpoints.
- Related Content: Hepion Pharma's NASH Candidate Aces Mid-Stage Study.
- Price Action: HEPA shares are up 16.9% at $1.94 during the premarket session on the last check Monday.
HEPAHepion Pharmaceuticals Inc
$0.42621.00%
Edge Rankings
Momentum
0.12
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
